AXDX — Accelerate Diagnostics Income Statement
0.000.00%
Last trade - 00:00- $13.36m
- $60.54m
- $11.70m
- 17
- 39
- 60
- 32
Annual income statement for Accelerate Diagnostics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 11.2 | 11.8 | 12.8 | 12.1 | 11.7 |
| Cost of Revenue | |||||
| Gross Profit | 4.46 | 4.12 | 3.3 | 3.73 | 2.7 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 74.9 | 73.5 | 72 | 79.3 | 46.3 |
| Operating Profit | -63.7 | -61.8 | -59.2 | -67.3 | -34.6 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -78.2 | -77.7 | -62.6 | -60.8 | -50.1 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -78.2 | -77.7 | -62.5 | -61.6 | -50 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -78.2 | -77.7 | -62.5 | -61.6 | -50 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -78.2 | -77.7 | -62.5 | -61.6 | -50 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -14 | -13.1 | -7.89 | -4.19 | -2.17 |